PhotoPharmics Phase 2 Parkinson’s Disease
April 16, 2026
PhotoPharmics will be attending the American Academy of Neurology Annual Meeting (AAN) in Chicago, April 18-22. PhotoPharmics’ pivotal Phase 3 Light for Parkinson’s Disease clinical trial is in its final weeks, and topline results will likely be shared at the World Parkinson Congress in late May. This fully remote, randomized, double-blind, placebo-controlled study is evaluating Celeste®, an investigational photo-neuromodulation device, in individuals living with Parkinson’s disease.
If you’ll be at AAN, drop by the PhotoPharmics Booth, #3614.
Recent News
- 2026 Life Sciences Awards to be Presented at the Mayer Brown Utah Life Sciences Summit
- PROGRESS TRIAL DEMONSTRATES EDWARDS TAVR IS SUPERIOR TO CLINICAL SURVEILLANCE FOR MODERATE AS PATIENTS WITH AT-RISK FEATURES
- Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
- Utah Business, Government Leaders Deepen Connections in Ireland
- Co-Diagnostics’ Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara’s SARAGENE® Test
- Merit Medical Acquires Solo Pace, Inc., Expanding Its Cardiac Therapies Platform with Innovative TAVR Pacing Technology
